On July 15, Merck rose 3.06% in regular trading, trading at $123.705/share, with turnover of $151 million. The rally was driven by the announcement that Keytruda met the primary endpoint in a Phase 3 clinical trial for mismatch repair-deficient advanced or recurrent endometrial cancer.

Specifically, Merck disclosed that Keytruda as monotherapy demonstrated a statistically significant improvement in progression-free survival compared with platinum doublet chemotherapy in previously untreated patients or those whose disease recurred more than six months after adjuvant therapy. An interim analysis also showed a trend toward improved overall survival, though the data were not yet mature. The safety profile remained consistent with prior studies, with no new safety signals identified.

The data further expands Keytruda's indication landscape in precision oncology. Recent momentum includes FDA approvals for Keytruda plus Padcev in muscle-invasive bladder cancer and Keytruda plus Trodelvy in first-line triple-negative breast cancer. Multiple investment banks have raised price targets, with Wells Fargo at $150, Scotiabank at $155, and RBC reiterating a $142 target with an outperform rating ahead of Q2 results on August 4.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)